On April 15, 2026, HHS Secretary Robert F. Kennedy Jr. announced a significant policy change in peptide regulation. The FDA will take 12 individual peptides off of Category 2 of the Bulk Drug Substances list and submit them to the Pharmacy Compounding Advisory Committee (PCAC) to be reviewed scientifically at subsequent meetings beginning in July 2026.
This ruling will aim to reinstate controlled access, minimize black-market dependence and enable third-party experts to assess each drug by clinical, pharmacological, and safety data.
Important Disclaimer:
All these peptides are not approved by the FDA to be used by humans. They are still investigational research compounds. This does not provide the approval or alter their legal status of personal or therapeutic use. The contents of this article are merely educational and research awareness.
Table of Contents
The History of Peptide Regulation: How We Got Here.
The control of peptides in the United States has changed a lot throughout the last ten years. Starting in 20172018, the FDA started to examine bulk drug substances that are used in compounding pharmacies under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It was aimed at isolating safe, well characterized compounds and those that may pose safety risks.
By 20232024, the FDA added lots of peptides to Category 2 because of the lack of enough safety data, immunogenicity risk, or because of the absence of standard manufacturing. This effectively limited the production of them by compounding pharmacies to be used by patients forcing many peptides into gray or black markets.
The announcement by Secretary Kennedy in 2026 is a turning point. The FDA will no longer have blanket restrictions, but rather will undertake targeted scientific reviews via the PCAC. This evidence-based solution is designed to strike a balance between patient safety and justifiable research and compounding requirements.
The 12 Peptides under Review.
The peptides that are transferred out of Category 2 to scientific review are:
- BPC-157
- Thymosin beta-4
- Epitalon (Epithalon)
- GHK-Cu
- MOTS-c
- DSIP
- Dihexa Acetate
- Ibutamoren Mesylate
- Melanotan II
- KPV
- Semax
- Cathelicidin LL-37
The compounds have been researched in preclinical and limited clinical studies in fields like tissue repair, immune modulation, neuroprotection and metabolic regulation.
The implications of this change on research.
To a legitimate researcher/laboratory, this may imply:
- Greater access to high-quality and regulated research material.
- Existence of more standardized compounding under supervision.
- Support of scientific assessment with complete clinical and safety information.
But this review process is not equal to FDA approval. A further application would still be restricted to research or under appropriate supervision compounding, and a comprehensive therapeutic approval would involve new, large clinical trials.
Why This Matters
The former Category 2 restrictions had pushed most of these peptides into unregulated markets, which posed safety issues since they could not be regulated in terms of quality. The new strategy will help re-subject these substances to scientific analysis and decrease the risks linked to the black market.
Secretary Kennedy stressed that the mission is to pursue science, implement the law, and provide the clarity that patients, providers, and pharmacies need.
Final Thoughts
In 2026, the move by FDA to take 12 peptides out of Category 2 to undergo scientific review is an important policy change. Although this can enhance access to valid research, it does not alter their status as research compounds.
The researchers need to stick to suppliers with a positive reputation and offer verified purity, third-party Certificates of Analysis, and transparent labeling as Research Use Only. Institutional guidelines and ethical research protocols must be followed to the letter.
To be up to date with the current developments, refer to official FDA announcement and reliable sources of science.
The above-mentioned peptides are purely laboratory and research peptides.
References
1. Secretary Kennedy (@SecKennedy) Official Statement on X, April 15, 2026.
2. FDA Review Begins: The Full List of 12 Peptides and What Happens Next
3. RFK Jr. Backs FDA Peptide Reversal; 12 Compounds Headed for Review
